close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Senate President Announces Major Legislation to Advance Massachusetts Health Care Reform

Electronic medical records and gift ban in place.

BOSTON, March 3, 2008 – Senate President Therese Murray, along with her colleagues in the Senate, today announced major health care legislation that will make Massachusetts a national leader in the statewide adoption of electronic medical records and the first in the country to impose an outright ban on pharmaceutical marketing gifts of any value.

The Senate bill, An Act to Promote Cost Containment, Transparency and Efficiency in the Delivery of Quality Health Care, also addresses the critical areas of primary care access, transparency and efficient use of resources and technology to drive down escalating costs in our health care system.

“This legislation represents a defining moment for the Commonwealth,” Senate President Therese Murray (D-Plymouth) said. “Our efforts today are crucial to the future vitality of our health care system and our economy, and this bill makes good on the promise I made in October to propose bold measures to ensure the success of health care reform in Massachusetts.

The Senate President made today’s announcement at the UMass Medical School in Worcester and was joined by Senator Richard Moore (Senate chair of the Joint Committee on Health Care Financing), other senators, health care stakeholders, and UMass officials and faculty members.

“If we expect to realize the full promise of the state's landmark health reform law – to achieve universal health coverage with safe, high quality and affordable care for all – this bill is vital,” said Senator Moore, who played a major role in drafting the legislation. “We must expand access to care, ensure a transparent system of quality improvement and cost containment, and improve the overall health of the people of Massachusetts.

“This legislation, which Senate President Murray and I are filing with the support of our legislative colleagues, will move us aggressively toward these important goals and keep our state in the forefront of national health reform efforts. Health Reform II is a prescription for a healthy Commonwealth.”

The Senate bill requires statewide adoption and compatibility of electronic medical records by 2015, backed by a public commitment of $25 million a year to accelerate the program. Physicians would have to show competency in the technology for medical board registration. The bill also sets a deadline of 2012 for statewide adoption of Computerized Physician Order Entry systems (CPOE). After this date, the use of CPOE would be required for hospital licensure.

“These initiatives will modernize the health care system, reduce waste and inefficiencies, and improve health care quality for every citizen of the Commonwealth,” President Murray said.

The gift-ban measure prohibits pharmaceutical agents from offering gifts and physicians from accepting gifts of any kind. The ban extends to physicians’ staff and family members. The legislation allows distribution of drug samples to doctors for the exclusive use of their patients.

“This bill is truly a collaborative effort,” President Murray said. “I want to congratulate senators Richard Moore, Mark Montigny, Karen Spilka, Robert O’Leary, Susan Fargo, Steven Baddour, Stephen Buoniconti, Gale Candaras, Steven Tolman and others who made this bill possible. I’m proud of the Senate’s work to make this a meaningful and comprehensive piece of legislation.”

Other highlights of the bill include:

  • An increase in the workforce capacity of nurses and primary care physicians through loan forgiveness programs and expanded enrollment at the state medical school. The bill also allows patients to choose nurse practitioners as their primary care providers.
  • A public-hearing requirement for hospitals and insurance companies to justify consumer costs and make cost-reduction recommendations. The legislation also authorizes public review of any insurance company submitting rate increases above 7 percent.
  • A statewide standard for uniform billing and coding among health care providers and insurance companies to reduce operational expenses of claims processing.
  • An enhanced “determination of need” process to help maintain standards of quality and ensure the efficient and equitable deployment of health care resources across the Commonwealth, avoiding the costly duplication of services.
  • A Purchasing Reform initiative to coordinate public and private “pay-for-performance” efforts to drive quality and efficiency in the market.
  • Authorization of the Department of Insurance to investigate the costs of medical malpractice coverage for health care providers.

State House, Room 332
Boston, MA 02133
Phone: 617.722.1500 Fax: 617.722.1076

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...